Compare SVV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVV | TRVI |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2021 | 2019 |
| Metric | SVV | TRVI |
|---|---|---|
| Price | $7.23 | $15.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $13.67 | ★ $21.55 |
| AVG Volume (30 Days) | 981.6K | ★ 1.8M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,678,954,000.00 | N/A |
| Revenue This Year | $6.91 | N/A |
| Revenue Next Year | $7.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.19 | N/A |
| 52 Week Low | $6.91 | $5.38 |
| 52 Week High | $13.89 | $16.12 |
| Indicator | SVV | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 65.92 |
| Support Level | $6.91 | $10.07 |
| Resistance Level | $8.95 | $16.12 |
| Average True Range (ATR) | 0.40 | 0.77 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 13.19 | 83.40 |
Savers Value Village Inc is a for-profit thrift operator in the United States and Canada. It purchases second-hand textiles (i.e., clothing, bedding, and bath items), shoes, accessories, housewares, books, and other goods from its non-profit partners (NPPs), either directly from them or via on-site donations (OSDs) at Community Donation Centers at its stores. The company then processes, selects, prices, and sells these items in its stores.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.